^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    evixapodlin (GS-4224)

    i
    Other names: GS-4224
    Associations

    News

    Trials
    Company:
    Gilead
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    3years
    Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1b/2, N=18, Terminated, Gilead Sciences | N=120 --> 18 | Trial completion date: May 2023 --> Mar 2021 | Recruiting --> Terminated | Trial primary completion date: Apr 2023 --> Mar 2021; Gilead decision to terminate
    Clinical • Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    evixapodlin (GS-4224)
    over3years
    Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1b/2, N=120, Recruiting, Gilead Sciences | Trial completion date: Aug 2022 --> May 2023 | Trial primary completion date: Jul 2022 --> Apr 2023
    Clinical • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    evixapodlin (GS-4224)
    almost4years
    Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1b/2, N=82, Recruiting, Gilead Sciences | Trial completion date: Dec 2021 --> Aug 2022 | Trial primary completion date: Nov 2021 --> Jul 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    evixapodlin (GS-4224)
    4years
    Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1b/2, N=76, Recruiting, Gilead Sciences | Trial completion date: Aug 2021 --> Dec 2021 | Trial primary completion date: Aug 2021 --> Nov 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    evixapodlin (GS-4224)